INTRODUCTION {#s1}
============

Brain tumor behavior is driven by aberrations in the genome and epigenome. Many, such as IDH mutations in diffuse low-grade glioma (DLGG) and aberrations in neurofibromatosis 2 (*NF2*) in hereditary and sporadic meningioma, are common among the same class of tumor ([@MCS004143WONC58]; [@MCS004143WONC11]; [@MCS004143WONC18]; [@MCS004143WONC7]; [@MCS004143WONC49]; [@MCS004143WONC69]). Knowledge of these aberrations has propelled the adoption of many into diagnostic neuropathology ([@MCS004143WONC49]). However, a given tumor may have other, less common genomic aberrations that are essential for its biological behavior, and knowledge of these may inform on the underlying biology, aberrant cellular pathways, and, most importantly, potential therapeutic agents ([@MCS004143WONC2]; [@MCS004143WONC20]; [@MCS004143WONC26]; [@MCS004143WONC66]). This genomics-based approach to the management of cancer patients, known as precision or personalized oncology, has established itself within the practice of oncology and is slowly making its way into neuro-oncology.

The publication of the *Update to the Fourth Edition of the WHO Classification of Tumors of the Central Nervous System* (WHO2016) was the culmination of discoveries made in the past decade ([@MCS004143WONC49]). These not only inform on tumor biology but can also significantly impact the diagnostic accuracy and prognosis and guide the most appropriate therapy. WHO2016 codifies and catalogs molecular biomarkers and integrates them within the traditional confine of "glass-based" diagnosis. Postsurgical management of patients, which may include chemoradiotherapy, relies on accurate diagnosis and grading, whereas genomic and epigenomic drivers have supplanted many of the classical histological descriptors in neuropathology. Importantly, the rapidly evolving genomic landscape leads to clonal heterogeneity and clinical behavior, contributing to treatment resistance ([@MCS004143WONC74]; [@MCS004143WONC38]). The dearth of effective systemic therapeutic agents presents a challenge for effective management.

The Personalized OncoGenomics (POG) initiative utilizes whole-genome and transcriptome analysis (WGTA) to identify and characterize these changes within a clinically meaningful time frame (4--6 wk from biopsy) in order to return results that may affect the treatment decision ([@MCS004143WONC42]). Coordinated effort was needed to develop a pipeline for processing biopsies of systemic metastatic specimens ([@MCS004143WONC42]), which account for 97.4% of all cases profiled. These challenges span multiple domains including tissue acquisition, pathology, sequencing, bioinformatic and analytic pipelines, and finally the unambiguous communication of actionable findings to the clinicians. However, the acquisition of CNS tumor samples remains challenging because of the location, invasiveness of the procedure, and intrinsic heterogeneity of the tumors. Here, we describe our experience of an "operating suite to sequencer" pipeline in the context of CNS tumors and discuss clinically informative findings from selected cases.

RESULTS {#s2}
=======

Patient Demographics {#s2a}
--------------------

In total, 16 adult patients (eight male, eight female) with recurrent CNS tumors were recruited from October 2013 to August 2017, constituting 2.61% (16/612) of all adult POG cases. Data was available for 14/16 cases. Reasons for lack of data include suboptimal tissue for WGTA or patient withdrawal from POG. A summary of patient data can be found in [Table 1](#MCS004143WONTB1){ref-type="table"} and [Figure 1](#MCS004143WONF1){ref-type="fig"}. All cases were profiled from tumor recurrences following initial treatments such as surgical resection, chemotherapy, and radiation therapy. WGTA was performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue in the absence of matched snap-frozen tissue (only applicable to ODG1 and ODG2). A summary of genomic findings per case can be found in [Table 2](#MCS004143WONTB2){ref-type="table"} and [Figure 2](#MCS004143WONF2){ref-type="fig"}. Data from selected cases will be presented. WGTA was also performed on 18 pediatric CNS tumors (25.7% \[18/70\] of all pediatric cases) and will be reported in a separate publication.

![Patient demographics. Pie charts showing the distribution of sex, tumor origin, tumor location (intra- vs. extra-axial), tumor location (brain hemisphere), tumor type, and tumor grade and a bar chart showing the frequency of age at diagnosis for all POG patients.](MCS004143Won_F1){#MCS004143WONF1}

![(*A*) Stacked bar chart showing total number of protein-coding single-nucleotide variants and truncating single-nucleotide variants identified in each POG case. (*B*) Stacked bar chart showing total number of insertion/deletion events and frameshift insertion/deletion events identified in each POG case. (*C*) Stacked bar chart showing the total number of structural variants and expressed fusion transcripts identified in each POG case. (*D*) (*Left*) Stacked bar chart comparing the total number of protein-coding single-nucleotide variants and truncating single-nucleotide variants identified in archived FFPE and fresh tumor in ODG1 and ODG2, both oligodendrogliomas. (*Right*) Stacked bar chart comparing the total number of insertion/deletions and frameshift insertion/deletions identified in archived FFPE and fresh tumor in ODG1 and ODG2, both oligodendrogliomas.](MCS004143Won_F2){#MCS004143WONF2}

###### 

Patient demographics and diagnoses of POG cases

  POG ID   Sex      Age at diagnosis   Diagnosis                                 WHO grade   Intra-/Extra-axial   Origin        Tumor side   Location
  -------- -------- ------------------ ----------------------------------------- ----------- -------------------- ------------- ------------ -------------------------------------
  MGM1     Female   48                 Metastatic meningioma                     II          Primary              Extra-axial   Left         Frontal lobe with orbital extension
  MGM2     Female   50                 Left petroclival meningioma               I           Primary              Extra-axial   Left         Petro-clival
  MGM3     Female   52                 Meningioma                                II          Primary              Extra-axial   Right        Sphenoid wing
  CHD1     Male     54                 Clival chordoma                           NA          Metastasis           Extra-axial   Midline      Clivus
  CHD2     Male     45                 Chordoma                                  NA          Metastasis           Extra-axial   Midline      Sacral spine
  CHD3     Female   18                 Chordoma                                  NA          Primary              Extra-axial   Midline      Clivus
  MPE1     Male     29                 Anaplastic myxopapillary ependymoma       NA          Primary              Extra-axial   Midline      Thoracic spine
  ODG1     Male     27                 Oligodendroglioma                         III         Primary              Intra-axial   Right        Frontal lobe
  ODG2     Female   29                 Oligodendroglioma                         II          Primary              Intra-axial   Right        Frontal lobe
  GBM1     Female   16                 Glioblastoma multiforme                   IV          Primary              Intra-axial   Left         Parietal lobe
  GBM2     Male     64                 Glioblastoma multiforme                   IV          Primary              Intra-axial   Left         Temporal lobe
  PXA1     Female   21                 Pleomorphic xanthoastrocytoma             II          Primary              Intra-axial   Right        Frontal lobe
  GNG1     Male     57                 Ganglioglioma of the left temporal lobe   II          Primary              Intra-axial   Left         Temporal lobe
  EPN1     Female   27                 Anaplastic ependymoma                     III         Primary              Intra-axial   Right        Occipital lobe
  EPN2     Male     18                 ependymoma                                III         Primary              Intra-axial   Right        Cingulate gyrus
  EPN3     Male     44                 Extramedullary spinal ependymoma          II          Primary              Intra-axial   Midline      Thoracic spine

###### 

Summary of genomic findings

  POG ID   Tumor type                      SNVs (truncating)   Indels (frameshift)   Structural variants (fusions expressed)   Mutation burden per Mb genome
  -------- ------------------------------- ------------------- --------------------- ----------------------------------------- -------------------------------
  MGM1     Meningioma                      22 (1)              5 (3)                 47 (1)                                    2.5660
  MGM2     Meningioma                      22 (4)              1 (1)                 55 (5)                                    2.3237
  CHD1     Chordoma                        33 (1)              3 (3)                 19 (1)                                    1.5275
  CHD2     Chordoma                        25 (2)              13 (11)               52 (2)                                    1.8623
  MPE1     Myxopapillary ependymoma        28 (2)              3 (1)                 144 (40)                                  1.1146
  ODG1     Oligodendroglioma               17 (1)              4 (3)                 12 (2)                                    2.4312
  ODG2     Oligodendroglioma               38 (0)              9 (8)                 36 (11)                                   1.6305
  GBM1     Glioblastoma                    24 (0)              9 (6)                 31 (9)                                    2.9786
  GBM2     Glioblastoma                    70 (3)              15 (12)               203 (27)                                  4.7236
  PXA1     Pleomorphic xanthoastrocytoma   97 (5)              10 (7)                74 (9)                                    2.3147
  GNG1     Ganglioglioma                   40 (5)              4 (4)                 64 (4)                                    2.4431
  EPN1     Ependymoma                      25 (1)              4 (3)                 31 (2)                                    1.8239
  EPN2     Ependymoma                      16 (2)              7 (5)                 65 (8)                                    0.9798
  EPN3     Ependymoma                      36 (2)              0 (0)                 61 (17)                                   2.4393

Extra-Axial Tumors {#s2b}
------------------

### Meningioma {#s2b1}

Meningiomas, the most common CNS neoplasia, are most often benign and treatable with surgical resection alone ([@MCS004143WONC31]; [@MCS004143WONC54]). However, ∼15%--20% present with more aggressive features such as brain invasion and mitotic activity ([@MCS004143WONC61]). Two recurrent meningiomas with anaplastic histologic features were enrolled following multiple local recurrences (MGM1) or metastasis (MGM2) despite surgical resections and radiation therapy. Transcriptomic analyses of both meningiomas revealed up-regulation of the MAPK and Wnt pathway (reported in up to 50% of meningiomas) as a result of *NF2* loss ([@MCS004143WONC9]; [@MCS004143WONC7]), a genomic feature identified in MGM2 but not MGM1. Interestingly, a fusion event identified in MGM1 involving *MN1* and *CXXC5* ([Supplemental Fig. 1A,B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004143/-/DC1)) was predicted by POG analyses to mimic *NF2,* resulting in up-regulation of the MAPK and Wnt pathways through FGF up-regulation and β-catenin activation, and derepression of several Wnt factors, respectively ([@MCS004143WONC44]). Fusions involving *MN1*, including an *MN1-CXXC5* fusion, have also been detected in a subset of *MN1-*altered primitive neuroectodermal tumors (PNETs) ([@MCS004143WONC65]). Interestingly, pathological assessment of MGM1 revealed inconsistent morphology and immunophenotypes across primary and recurrent biopsies. The primary tumor was diagnosed as an atypical meningioma, one recurrence was diagnosed as a PNET, and another recurrence was diagnosed as a malignant neoplasm with neuroendocrine differentiation. However, a unifying diagnosis of atypical meningioma was given because of consistent immunopositivity for SSTR2, a specific marker for meningothelial neoplasms ([@MCS004143WONC51]), across the primary and all recurrent samples. Epigenetic dysregulation (*KDM3B* and *DNMT1* in MGM1; *KMT2D, ARID1A, ARID1B*, and *EP300* in MGM2) was detected in both tumors, consistent with published findings in anaplastic meningioma ([@MCS004143WONC7]). Therapeutic targets identified were FGF/FGFR in MGM1 and MEK in MGM2. A summary of pathway analyses and therapeutic targets identified for each case can be found in [Table 3](#MCS004143WONTB3){ref-type="table"}.

###### 

Dysregulated pathways and potential therapeutic targets

  POG ID   Tumor type                      Pathways dysregulated                                                Oncogenic drivers                Therapeutic targets       Drug available                                        Potential caveats
  -------- ------------------------------- -------------------------------------------------------------------- -------------------------------- ------------------------- ----------------------------------------------------- -------------------------------------------------
  MGM1     Meningioma                      MAPK, NOTCH, Wnt, DNA methylation                                    *FGF4, FGFR3, MN1-CXXC5*         *FGF/FGFR*                Erlotinib, afatinib                                   NA
  MGM2     Meningioma                      MAPK, insulin signaling, Wnt, cell cycle, epigenome                  *MAP2K2, EEF2*                   *MEK2*                    Trametinib, cobimetinib                               NA
  CHD1     Chordoma                        MAPK, cell cycle                                                     *Brachyury*                      *Brachyury, Fos/Jun*      Tarmogen, nadroparin/irbesartan                       NA
  CHD2     Chordoma                        MAPK, cell cycle                                                     *Brachyury*                      *Brachyury, RTK*          Tarmogen, imatinib/afatinib                           NA
  MPE1     Myxopapillary Ependymoma        MAPK, PI3K/AKT/mTOR, cell cycle, TGF-β, NOTCH                        *ABL1, FIP1L1, PDGFRA, HIF1A*    *PDGFRα, ABL1, FIP1L1*    Imatinib                                              Downstream effects unknown
  ODG1     Oligodendroglioma               MAPK, DNA methylation, NOTCH, PI3K/AKT/mTOR                          *IDH1, EGFR, ETV1/4/5, DLL3*     *EGFR/Fyn*                Cetuximab + dasatinib                                 CIC loss may subvert upstream MAPK inhibition
  ODG2     Oligodendroglioma               MAPK, DNA methylation, NOTCH, PI3K/AKT/mTOR                          *IDH1, EGFR, PDGFRA/B, DLL1/3*   *VEGF, PDGFRα/β*          Sorafenib/sunitinib, becaplermin/imatinib/dasatinib   CIC loss may subvert upstream MAPK inhibition
  GBM1     Glioblastoma                    MAPK, chromatin remodeling, cell cycle, mismatch repair, MYC, PI3K   *IDH1, PI3K, TP53, CDK4*         *PIK3Cα*                  Idelalisib                                            NA
  GBM2     Glioblastoma                    MAPK, PI3K, cell cycle                                               *EGFR, PTEN, CDKN2A*             *EGFR*                    Erlotinib, afatinib, dacomitinib, cetuximab           PTEN loss may cause resistance to EGFR Ab
  PXA1     Pleomorphic xanthoastrocytoma   MAPK, PI3K/AKT, cell cycle                                           *BRAF V600E*                     *BRAF*                    Dabrafenib, trametinib                                NA
  GNG1     Ganglioglioma                   MAPK, DNA damage, Hedgehog                                           *PTEN, NF1, BRCA1, Brachyury*    *PARP*                    Olaparib                                              NA
  EPN1     Ependymoma                      MAPK, NOTCH, cell cycle, Hedgehog, mismatch repair                   *EWSR1-PATZ1*                    *PDGFR/FGFR*              Imatinib, erlotinib, afatinib, cetuximab              NA
  EPN2     Ependymoma                      MAPK, NF-κB, DNA damage repair, hypoxia, NOTCH, Wnt, cell cycle      *C11orf95-RELA, CCND1/3*         *C11orf95-RELA. PD-L1*    Pembrolizumab                                         NA
  EPN3     Ependymoma                      MAPK, Wnt, NOTCH, chromatin remodeling, mismatch repair              No clear driver                  *ERBB2, KIT/ABL1, FGFR*   Imatinib, lapatinib                                   Lapatinib found to be ineffective in ependymoma

### Chordoma {#s2b2}

Chordomas are highly recurrent and treatment-resistant bone tumors that are thought to be of notochordal descent ([@MCS004143WONC68]; [@MCS004143WONC70]). POG analyses were performed on one primary clival chordoma (CHD1) and one sacral metastasis of a clival chordoma (CHD2). Transcriptomic and pathway analyses identified overexpression of *Brachyury*, a hallmark of chordoma ([@MCS004143WONC68]), and activation of the MAPK pathway through *EGFR* amplification in both cases. Interestingly, up-regulation of the oncogenic transcription factors *FOS* and *JUN* was identified in CHD1, downstream from MAPK. Both cases also harbored dysregulation of cell cycle genes including homozygous loss of the cell cycle regulators *CDKN2A*/*B* in CHD1 and *RB1* in CHD2. Copy-number gain of *ETV1* and up-regulation of *SNAI1* was also identified in CHD2, which may explain the increased metastatic potential and invasiveness ([@MCS004143WONC46]). Although each chordoma harbored unique genomic and transcriptomic aberrations, therapeutic options for both cases were to target *Brachyury* directly and indirectly through *FGFR*.

### Myxopapillary Ependymoma {#s2b3}

Myxopapillary ependymomas are rare, slow-growing tumors associated with the conus medullaris, cauda equina, and filum terminale of the spinal cord and rarely show anaplastic features ([@MCS004143WONC48]). Our patient MPE1 presented histologically with a recurrent disseminated anaplastic myxopapillary ependymoma ([@MCS004143WONC5]; [@MCS004143WONC35]; [@MCS004143WONC45]) following multiple surgical resections and radiation therapy. WGTA revealed copy-number losses of *NF2*, *MSH3*, *PTEN*, *RB1*, and *CDKN1B*. Transcriptomic analyses showed up-regulation of several RTKs including *NTRK2*, *NRG2*, *ABL1*, *PDGFRA*, and *FIP1L1*. Other dysregulated pathways included Notch and Wnt activation, most likely because of the *NF2* loss ([@MCS004143WONC7]). Top therapeutic targets included the RTKs *ABL1*, *PDGFRA*, and *FIP1L1.* However, the downstream effects were unclear from our transcriptomic and pathway analyses. POG analyses of rare tumors such as this case not only inform of potentially actionable targets, they also provide insight into the intrinsic genomic and transcriptomic landscape of these tumors.

Surgical resection remains one of the best predictors of outcome in many extra-axial tumors, in part because of a lack of durable and effective systemic or targeted therapies and the benign nature of many extra-axial tumors ([@MCS004143WONC70]; [@MCS004143WONC8]; [@MCS004143WONC56]). However, targeting of specific members of the MAPK and RTK signaling cascade may be an effective strategy moving forward, as evidenced by our cohort of extra-axial POG cases. Representative histologic, radiologic, and select genomic findings for select extra-axial cases can be found in [Figure 3](#MCS004143WONF3){ref-type="fig"}.

![Extra-axial collage showing MRI scans, histology, and a genomic finding of interest for select cases. Cases are presented from *top* to *bottom* as follows: (CHD1) chordoma (high *FOS*/*JUN* expression), (CHD2) chordoma (high *T* and *MET* expression), (MGM1) orbital meningioma (*MN1-CXXC5* fusion), (MGM2) meningioma (*NF2* loss), (MPE1) anaplastic myxopapillary ependymoma (*NF2* loss).](MCS004143Won_F3){#MCS004143WONF3}

Intra-Axial Tumors {#s2c}
------------------

### Ependymoma {#s2c1}

Ependymomas are glial tumors that occur along the neuraxis. Treatment success is largely affected by tumor location ([@MCS004143WONC54]), as surgery remains the most effective treatment ([@MCS004143WONC52]). Three recurrent adult ependymomas, two originating from the brain (EPN1, EPN2) and one originating from the spine (EPN3), were enrolled. WGTA revealed all three to be heavily driven by recurrent copy-number loss or down-regulation in cell cycle regulators/DNA repair genes and copy-number gains or high-expression outliers of several RTKs. A *C1orf53*/*C11orf95*-*RELA* fusion, an oncogenic driver fusion reported in up to 70% supratentorial ependymomas ([@MCS004143WONC57]), was detected in EPN2. Interestingly, a novel *EWSR1-PATZ1* fusion was identified and validated in EPN1 ([Supplemental Fig. 1C,D](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004143/-/DC1)), which was predicted, using pathway analyses, to behave biologically similar to *RELA* fusion through activation of the mTOR and MAPK pathways. Activation of NF-κB and subsequent cell cycle up-regulation, downstream hallmarks of *RELA* fusions, were also identified in EPN1 and EPN2. Potential therapeutic targets for all three cases involved targeting the RTK and MAPK signaling cascades, which have been previously reported using imatinib ([@MCS004143WONC19]) and lapatinib ([@MCS004143WONC22]).

### Oligodendroglioma {#s2c2}

Oligodendrogliomas (ODGs) are DLGGs molecularly defined by IDH mutation and 1p19q-co-deletion, and associated with favorable prognosis ([@MCS004143WONC34]; [@MCS004143WONC11]; [@MCS004143WONC66]; [@MCS004143WONC49]). Two patients (ODG1, ODG2) were enrolled following multiple resections and systemic/radiation therapy. For these two cases, we were also able to investigate tumor evolution by performing WGTA using fresh tumor from the latest resection and archival FFPE tissue. Comparison of fresh and FFPE ODG1 samples identified several shared molecular characteristics including 1p19q-co-deletion, *IDH1* R132H, and *TET2* mutations. Fresh ODG1 also harbored a *CIC* R215W mutation, a more recent molecular marker of ODG ([@MCS004143WONC6]; [@MCS004143WONC75]), suggesting tumor evolution toward a more aggressive phenotype ([@MCS004143WONC14]; [@MCS004143WONC24]; [@MCS004143WONC55]; [@MCS004143WONC43]; [@MCS004143WONC73]). Conversely, comparison of fresh and FFPE tissue from ODG2 revealed *IDH1* R132H as the only shared mutation, suggesting dramatic tumor evolution. Archival ODG2 tissue harbored missense mutations in *TP53*, *ATRX*, and *PI3CK* and lacked detectable 1p deletion; whereas 1p19q-co-deletion and a *CIC* frameshift mutation were detected in the fresh ODG2. Analyses of both cases revealed up-regulation of *SOX2*, and *OLIG2*, indicative of an oligodendroglial fate, and up-regulation of the MAPK signaling pathway and the ETS transcription factors (*ETV1/4/5*), likely a result of CIC inactivation ([@MCS004143WONC37]; [@MCS004143WONC53]; [@MCS004143WONC43]; [@MCS004143WONC73]). Although both ODG cases only shared mutations in *IDH1*, *CIC*, 1p19q-co-deletion, the transcriptomic and pathway analyses revealed striking similarities, suggesting that the biology of ODG is driven heavily by these three genomic aberrations. A summary of clinically informative or useful molecular findings in our two primary and recurrent ODG samples is summarized in [Table 4](#MCS004143WONTB4){ref-type="table"}. Top therapeutic candidates included EGFR, MEK, and PI3K. However, inhibition of upstream RTK components may be precluded by CIC inactivation ([@MCS004143WONC43]; [@MCS004143WONC71]), making systemic therapies particularly vexing once the tumor develops resistance to standard chemotherapeutic agents such as temozolomide.

###### 

Molecular findings of primary and recurrent ODG samples

                    ODG1      ODG2                                      
  ----------------- --------- ------------- ------------- ------------- -------------
  *IDH1*            WGS       R132H (38%)   R132H (45%)   R132H (25%)   R132H (42%)
  *TERT* promoter   WGS       WT            C250T (43%)   WT            C228T (38%)
  1p19q             LOH PCR   LOH           --            LOH           --
  1p19q             FISH      --            LOH           --            LOH
  1p19q             WGS       LOH           LOH           ROH           LOH
  *CIC*             WGS       WT            R215W         WT            P97\*fs

### Glioblastoma {#s2c3}

GBM1 (\<20 yr of age) was positive for *IDH1* R132H and *ATRX/TP53* loss-of-function mutations---genomic characteristics suggestive of an astrocytic precursor lesion ([@MCS004143WONC58]; [@MCS004143WONC10]). Conversely, GBM2 (\>60 yr of age) presented with *EGFR* amplification, a genomic characteristic of primary GBM in the elderly ([@MCS004143WONC32]; [@MCS004143WONC1]). Copy-number losses in the cell cycle genes (*PTEN* -- GBM1, *PTEN/CDKN2A* -- GBM2) and copy-number gains of cell cycle/signaling genes (*ACVR1B* \[39 copy gains\], *CCND1* -- GBM1; *EGFR* \[103 copy gains\], *BRAF* -- GBM2) were identified in both cases. Low-percentile expression (0%--22%) of DNA mismatch repair genes (*MSH2/6*, *MLH1/3*, *PMS1/2*) and *MGMT* were identified in GBM1, suggesting impaired DNA damage repair and predicted response to TMZ ([@MCS004143WONC32]; [@MCS004143WONC10]). Although GBM1 originated from DLGG, the oncogenic drivers identified in both cases were similar, which may suggest convergent evolution regardless of the precursor lesion. GBM remains a difficult disease to treat because of a lack of efficient and effective drug delivery.

Intra-axial tumors are often particularly challenging to treat because of their location and infiltrative nature. Many tumors that initially respond ultimately develop treatment resistance as a result of tumor heterogeneity and clonal evolution ([@MCS004143WONC74]; [@MCS004143WONC63]; [@MCS004143WONC38]; [@MCS004143WONC66]). Similar to extra-axial tumors, analyses of intra-axial tumors revealed that the majority of tumors, regardless of pathology, are driven by activation of the RTK/MAPK pathways and inactivation of cell cycle regulators (TP53/CDKN family). Targeting specific components of the MAPK pathway may be a viable therapeutic option in the future, as new treatment delivery methods are developed to circumvent the blood--brain barrier. Representative histologic, radiologic, and select genomic findings for select extra-axial cases can be found in [Figure 4](#MCS004143WONF4){ref-type="fig"}. Genomic variants for each case discussed can be found in [Table 5](#MCS004143WONTB5){ref-type="table"}.

![Intra-axial collage showing MRI scans, histology, and a genomic finding of interest for select cases. Cases are presented from *top* to *bottom* as follows: (ODG1) oligodendroglioma (1p19q co-deletion in primary and recurrent tissue), (GBM1) IDH mutated recurrent glioblastoma (*PI3KCA*-activating missense mutation), (EPN1) supratentorial ependymoma (*EWSR1-PATZ1* fusion), (EPN2) ependymoma (*RELA* fusion), (PXA1) pleomorphic xanthoastrocytoma (high *PDL1* expression).](MCS004143Won_F4){#MCS004143WONF4}

###### 

Variant table

  Gene               Chromosome             HGVS DNA reference                                                              HGVS protein reference   Variant type   Predicted effect (substitution, deletion, etc.)   dbSNP/dbVar ID   ClinVar ID     Genotype (heterozygous/homozygous)   Parent of origin (optional)
  ------------------ ---------------------- ------------------------------------------------------------------------------- ------------------------ -------------- ------------------------------------------------- ---------------- -------------- ------------------------------------ -----------------------------
  *MN1;;CXXC5*       t(5;22)(q31.2;q12.1)   22:28192751\| 5:139060788                                                       --                       SV             Translocation                                                      SCV000920879   NA                                   MGM1
  *DNMT1*            19                     19:10265450 C\>A                                                                p.Xnspl                  SNV            Splice site                                                        SCV000924575   Heterozygous                         MGM1
  *KMT2D*            12                     12:49427441 G\>A c.11047C\>T                                                    p.Q3683\*                SNV            Stop                                                               SCV000924576   Heterozygous                         MGM2
  *MSH3*             5                      5:79950724 G\>C c.178G\>C                                                       p.A60P                   SNV            Substitution                                                       SCV000924577   Heterozygous                         MGM2
  *MN1*              22                     c.785delG                                                                       p.G262fs                 Indel          frameshift                                                         SCV000924571   Subclone                             CHD1
  *MN1*              22                     c.772_776delCATTA                                                               p.H258fs                 Indel          Frameshift                                                         SCV000924572   Subclone                             CHD1
  *EWSR1::PATZ1*     inv(22)(q12.2)         22:29684716 EWSR1-001(ENST00000397938) 22:31740655 PATZ1-001(ENST00000266269)   --                       SV             Inversion                                                          SCV000920877   NA                                   EPN1
  *C11orf95::RELA*   dup(11)(q13.1)         11:63533279\| 11:65429676                                                       --                       SV             Duplication                                                        SCV000920878   NA                                   EPN2
  *CHD6*             6                      c.3296G\>A                                                                      p.R1099Q                 SNV            Substitution                                                       SCV000924579   Heterozygous                         EPN3
  *CIC*              19                     c.643C\>T                                                                       p.R215W                  SNV            Substitution                                                       SCV000924567   Heterozygous                         ODG1
  *IDH1*             2                      c.395G\>A                                                                       p.R132H                  SNV            Substitution                                      rs121913500                     Heterozygous                         ODG1
  *IDH1*             2                      c.395G\>A                                                                       p.R132H                  SNV            Substitution                                      rs121913500                     Heterozygous                         ODG2
  *CIC*              19                     c.289delC                                                                       p.P98fs                  Indel          Frameshift                                                         SCV000924568   Heterozygous                         ODG2
  *TP53*             17                     c.319T\>G                                                                       p.Y107D                  SNV            Substitution                                      rs368771578                     Homozygous                           ODG2
  *ATRX*             X                      c.4213A\>G                                                                      p.R1405G                 SNV            Substitution                                                       SCV000924569   Heterozygous                         ODG2
  *IDH1*             2                      c.395G\>A                                                                       p.R132H                  SNV            Substitution                                      rs121913500                     Heterozygous                         GBM1
  *TP53*             17                     c.725G\>A                                                                       p.C242Y                  SNV            Substitution                                      rs121912655                     Heterozygous                         GBM1
  *TP53*             17                     c.524G\>A                                                                       p.R175H                  SNV            Substitution                                      rs28934578                      Heterozygous                         GBM1
  *ATRX*             X                      c.6440G\>T                                                                      p.S2147I                 SNV            Substitution                                                       SCV000924570   Heterozygous                         GBM1
  *PTEN*             10                     c.697C\>T                                                                       p.R233\*                 SNV            Stop                                              rs121909219                     Homozygous                           GBM2
  *EGFR*             6                      c.3056C\>A                                                                      p.P1019Q                 SNV            Substitution                                                       SCV000924573   Heterozygous                         GBM2
  *EGFR*             6                      c.3055C\>A                                                                      p.P1019T                 SNV            Substitution                                                       SCV000924574   Heterozygous                         GBM2
  *NF1*              17                     c.6852_6855delTTAC                                                              p.Y2264Tfs               Indel          Frameshift                                                         SCV000924578   Homozygous                           GNG1
  *BRAF*             7                      c.1799T\>A                                                                      p.V600E                  SNV            Substitution                                      rs113488022                     Heterozygous                         PXA1

DISCUSSION {#s3}
==========

Genomic Fusions and Transcriptomic Implications {#s3a}
-----------------------------------------------

Genomic instability, a hallmark of cancer ([@MCS004143WONC30]), can result in structural aberrations such as fusions, which can drive cancers. With the increasing accessibility of genomic studies, testing of prognostically informative fusions such as *FGFR3-TACC1* and *NTRK* fusions in GBM is becoming more available ([@MCS004143WONC64]; [@MCS004143WONC25]). It is also becoming more evident that fusion partners behave much more promiscuously than previously appreciated and have the potential to drive oncogenesis in several cancer types, such as the *EWSR1-PATZ1* fusion identified in EPN1, which has been previously reported in small round cell sarcoma ([@MCS004143WONC12]) and ganglioglioma ([@MCS004143WONC60]). Fusions involving *EWSR1* have also been identified in CNS PNETs ([@MCS004143WONC65])

In our cohort, genomic fusions and fusion transcripts were detected in all cases. The challenge lies in properly identifying those that are clinically and/or biologically informative. The usage of whole-transcriptome data, in POG, has been essential to the discovery of suspected driver fusions. For example, the *MN1-CXXC5* fusion identified in MGM1 was first identified in the transcriptome and was not detected in the genome because of a complicated set of inversions and translocations involving *MN1*, *CXXC5*, and *KDM3B*. Within the POG analytic pipeline, fusion transcripts are evaluated for significance by integrating pathway analyses, transcriptome data, predicted protein structure, and published literature. Without the addition of RNA-seq to POG, oncogenic drivers and potential therapeutic targets would not have been identified in many cases.

The Role of the Neurosurgeon in Personalized Oncology {#s3b}
-----------------------------------------------------

From the neurosurgeon\'s perspective, the most immediate effect on practice is likely the increased demand for tissue sampling, particularly in poorly accessible and recurrent tumors that can harbor significant progression in the molecular features ([@MCS004143WONC39]). From this there are two important conclusions---first, that repeat sampling of recurrent tumors is likely necessary to guide targeted therapy and, second, that sampling from a single region in tumors, such as diffuse glioma, is unlikely to fully represent tumor biology. The role of surgery in the management of recurrent glioma is controversial given that these tumors tend to recur in deeper or distant locations, reducing the feasibility of significant debulking ([@MCS004143WONC72]; [@MCS004143WONC16]).

The greater challenge, now, is developing tissue sampling strategies that adequately represent the heterogeneity of a given tumor and provide sufficient material for genomic analyses. This is already recognized as an issue in tumor grading, whereby sampling of a peripheral region of lower grade can lead to misdiagnosis ([@MCS004143WONC36]). Neuroimaging in conjunction with machine learning analysis of radiological images may be an important tool in optimizing tissue acquisition ([@MCS004143WONC47]) as will MRI-guided open biopsy to ensure representative sampling ([@MCS004143WONC23]). Stereotactic and intraoperative MRI-guided biopsies have also similar diagnostic yield and safety ([@MCS004143WONC50]). Regardless of the approach, minimally invasive biopsies have an intrinsic barrier to reaching sufficiently representative regions of the tumor. For many tumors, a single-needle trajectory likely will not suffice, necessitating multiple passes and increased risk of injury. With the rapid growth of next-generation sequencing, future analyses may require less tissue but may not recapitulate the heterogeneous nature of tumors, especially diffusely infiltrative tumors such as GBM. Therefore, surgical expertise is still required to accrue sufficient and representative tissue for molecular analyses.

Tissue Banking Moving Forward {#s3c}
-----------------------------

With the emergence of single-cell genomic and transcriptomic profiling, the methods of banking tumor tissue have become more pertinent in determining the feasibility and quality of these studies. Previous studies investigating the single-cell heterogeneity and clonal hierarchy of gliomas have utilized fresh tissue to minimize the effects of storage and preservation on cell viability and the transcriptome ([@MCS004143WONC59]; [@MCS004143WONC67]; [@MCS004143WONC21]). However, many groups have also started to investigate methods of preservation that allow for molecular analyses at a single-cell resolution without compromising the quality of the data such as cryopreservation ([@MCS004143WONC28]), fixation ([@MCS004143WONC4]), and even archival FFPE tissue ([@MCS004143WONC29]). Therefore, going forward, the methods used to bank surgical tissues should be revisited to accommodate studies that aim to utilize single-cell technologies to further study tumor heterogeneity and evolution in a clinical setting as precision medicine moves toward assessing the drivers of each individual tumor at a greater resolution.

Precision Medicine in Neuro-Oncology {#s3d}
------------------------------------

Genomic drivers and prognostic markers have been integrated into routine clinical workups for several CNS tumors such as IDH mutation in DLGG. However, the genomic and transcriptomic events that drive tumor recurrence, treatment resistance, and metastatic potential can be unique for each individual tumor. The POG program is able to characterize these genomic and transcriptomic drivers within a clinically meaningful time frame of 4--6 wk to determine the best therapeutic course for the patient. That said, the bioinformatic expertise and manpower required to analyze and present the data in a practical and clinically useful format remains a bottleneck for POG. Although POG analyses often find potentially actionable therapeutic targets, in CNS cases, implementation of these targeted therapies into the clinic has been hindered by the lack of available clinical trials and the lack of drugs capable of penetrating the blood--brain barrier. None of the CNS-POG cases included in this report received POG-guided therapies. In contrast, for non-CNS patients, the POG program has been regarded as a success, with ∼70% of patients receiving a POG-informed therapy and half of those treated achieving some disease control ([@MCS004143WONC42]). These results clearly emphasize the need for developing targeted therapies or delivery methods that are able to effectively cross the blood--brain barrier and access CNS tumors. Regardless, the WGTA generated from our small cohort of CNS POG cases has provided an opportunity to further study the genomic and transcriptomic landscape of these recurrent tumors.

Our program only enrolled patients with recurrent tumors, but as the benefits of personalized oncology continue to be demonstrated and, importantly, as more effective targeted therapies are developed, this approach will likely make its way into the treatment of primary tumors, necessitating a shift in surgical strategy, to, at the very least, differentially label tissue samples from different regions of the tumor in order to recapitulate tumor heterogeneity. The need for correlation of imaging, intraoperative findings, and molecular analysis underscores the importance of close collaboration between radiologists, surgeons, and pathologists. Further down the pipeline, the process of analyzing and formulating an actionable treatment plan requires clear communication between pathologists, molecular biologists, bioinformaticians, and oncologists. Personalized oncology is thus truly a multidisciplinary field, one in which neurosurgeons must play a vital role if these programs are to succeed and benefit our patients.

METHODS {#s4}
=======

Patient Recruitment and Tissue Accrual {#s4a}
--------------------------------------

The study was approved by and adhered to the University of British Columbia Research Ethics Committee (REB\# H12-00137 and H14-00681-A019) as part of the Personalized OncoGenomics program of British Columbia (NCT02155621). Written informed patient consent was obtained by a participating oncologist prior to comprehensive genomic profiling. Cases were selected based on factors including exhaustion of treatment options and progressive disease despite multiple conventional treatments. Recruitment of brain tumor patients must also take into consideration the ease of tissue access. Patients were recruited with the understanding that information and results from these analyses are experimental and may not result in actionable treatments. All tissue acquisition procedures were conducted during scheduled surgeries, whereas a small number of cases utilized banked tissue from previous neurosurgical procedures. All tissue specimens were rushed to pathology from the operating room, where the on-call neuropathologist assessed the tissue for sufficient viable tumor (∼55% tumor), quality, and adequacy for standard clinical diagnostic workup. Materials were sent directly for DNA/RNA extraction or snap frozen for storage.

POG Sequencing and Analytic Pipeline {#s4b}
------------------------------------

DNA and RNA were extracted from tumor tissue and matched whole blood, used as a germline reference. Whole-genome (∼40-fold sequence coverage for germline and \>80-fold coverage for tumor; see [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004143/-/DC1)) and transcriptome (tumor, ∼200 million reads) sequencing analysis were performed on the Illumina HiSeq platform ([@MCS004143WONC42]). Somatic mutations, small insertions or deletions, copy-number alterations, and structural variants were detected using a bioinformatic pipeline as previously described ([@MCS004143WONC40]).

Identification of Potential Therapeutic Targets {#s4c}
-----------------------------------------------

To identify candidate therapeutic targets, an initial automated matching of genes and variants to a database of known drug--gene and drug--variant associations was performed. Relevant gene alterations include small mutations, copy changes, structural variants, and expression alterations. Genes with expression alterations are identified by comparison of gene expression to reference sets, including normal expression values from the Illumina Human Body Map 2.0 project ([www.illumina.com](www.illumina.com); ArrayExpress ID: E-MTAB-513) ([@MCS004143WONC3]), and cancer expression values from The Cancer Genome Atlas (<https://tcga-data.nci.nih.gov/tcga/>) ([@MCS004143WONC33]). Genes with expression in a matched cancer type greater than the 70th percentile compared to the matched cancer type and at least twofold increased expression relative to normal tissue, or with expression less than the 30th percentile and at least twofold reduced relative to normal tissue, are considered potentially over- or underexpressed; those with \>90th- or \<10th-percentile expression are considered candidate low- or high-expression outliers. The database of known drug--gene and drug--variant associations is an expert-curated in-house knowledgebase describing therapeutic, diagnostic, prognostic, and biological associations from the literature, from experience with previous patients within the POG program ([@MCS004143WONC42]), curated from automated natural-language processing through CIVICmine (<http://bionlp.bcgsc.ca/civicmine/>; <https://www.biorxiv.org/content/10.1101/500686v1>), and drawing on other curated sources including OncoKB ([@MCS004143WONC13]), CIViC ([@MCS004143WONC27]), and the MD Anderson Knowledgebase for Precision Oncology ([@MCS004143WONC17]).

Genes are also associated with pathways in cancer using ConsensusPathDB ([@MCS004143WONC41]) and the COSMIC cancer gene census ([@MCS004143WONC62]), and additional gene--drug associations are identified using DGIdb ([@MCS004143WONC15]). The automated matching of genes and variants to potential therapeutics is then reviewed and extended by expert manual review, including review of novel mutations and fusions for likely functional effect, identification of dysregulated pathways based on multiple alterations or alterations that propagate to pathway outputs, examination for highly unusual or targetable extreme expression outliers, identification of drugs that may indirectly impact driver alterations, and considerations of levels of evidence such as clinical trial or preclinical data and tumor type context. Analyzed data including genomic aberrations and expression profiles were then compiled into a standardized report including any informative and potentially actionable features ([@MCS004143WONC42]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The whole-genome and transcriptome sequencing data for these cases are available as .bam files from the European Genome-phenome Archive (EGA; [www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) as part of the study EGAS00001001159. Interpreted variants including fusions have been deposited into ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under the accession numbers listed in [Table 5](#MCS004143WONTB5){ref-type="table"}.
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